Some customers allege that Mochi Health made misleading claims about the FDA approval status and safety profile of their compounded GLP-1 products. When purchasing through Mochi Health’s platform, some customers claim they were told the medication was “FDA-approved,” “generic Ozempic,” or “clinically proven” — or that it contained the “same active ingredient” as FDA-approved alternatives — without clear disclosure that the medication was compounded and not FDA-approved. The claims allege this was deceptive and violated consumer protection laws.
If you believe you qualify, complete the form below to learn if you may be eligible to pursue a claim:
- Age Requirement: You are 18 years or older.
- Mochi Health Customer: You purchased a compounded GLP-1 weight loss product from Mochi Health on or after May 2023.
- Compounded Injectable: You received a compounded semaglutide, compounded tirzepatide, or compounded liraglutide — not an FDA-approved branded medication like Ozempic®, Wegovy®, Mounjaro®, Zepbound®, or Saxenda®.
If you believe you have been impacted, here’s what you can do:
- Gather Your Information: Collect receipts, email confirmations, app purchase history, bank or credit card statements, or screenshots showing your Mochi Health account and purchases of the compounded GLP-1 medication.
- Recall Your Experience: Have ready your Mochi Health account email address, the state where you resided when you made your purchases, and the payment method you used (credit/debit card, PayPal, or other third-party payment).
- Complete the Form; If you believe you qualify, complete the form and submit your information to learn if you may qualify to pursue compensation.